NV-PROOVSTATION
9.1.2020 16:34:11 CET | Business Wire | Press release
Plans are being implemented for up to 40 inspection portals to be deployed across the BCA Group, starting in February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200109005586/en/
At the 2020 CES in Las Vegas, ProovStation and BCA Group, Europe’s leading vehicle remarketing company, today confirmed a commercial agreement to implement ProovStation inspection portals in BCA auctions and logistics compounds across Europe. The roll-out, which is planned to cover 13 countries, will commence in February.
Thanks to industry-leading artificial intelligence, ProovStation portals will allow BCA to carry out a fully automated damage inspection, including underneath the vehicle, within 3 seconds. As the car drives through the portal, even millimeter-large scratches can be spotted, increasing precision and cost-efficiency.
“We are proud to have been chosen by BCA Group as their site based volume inspection partner. The trust from Europe’s largest seller of used cars is a strong signal of legitimacy for ProovStation and confirms the value of our solutions for the automotive industry in its widest definition. This first large contract is a motivation booster for our team, and we will continue to work hard at revolutionising the vehicle inspection process. We want to turn ProovStation into the international standard in the inspection process for the main market segments: OEM, dealers, rental and logistics service providers ” says Cédric BERNARD, CEO of ProovStation.
Jean-Roch PIAT, Divisional CEO of BCA Europe added: “As the leading marketplace for used vehicles across Europe, BCA is providing the power of accurate real-time decision intelligence capability that connects every aspect of buying and selling with BCA, Europe’s largest used vehicle marketplace. ProovStation AI-powered inspection technology allows us to further increase the accuracy of the damage recognition, at unprecedented levels of speed and unit cost to benefit our customers .”
ABOUT PROOVSTATION
ProovStation automates and standardizes the global automotive inspection process. ProovStation is an automated drive-through bay which detects and analyses vehicle damages. The system generates a 360-degree photo scan of the vehicle in less than 3 seconds and increases the accuracy of damage recognition while reducing inspection costs and greatly improving trust during the transfer of liability. It also offers extra services from a user-friendly dashboard including repair estimate, inspection comparison log, used car pricing, integration and KPI tracking, insurance report and other fully customized options.
OFFICIAL COMMERCIAL LAUNCH AT CES 2020
For its second participation at the CES, the ProovStation start-up returns to Las Vegas with a finalised product, the official launch for mass production, and the determination to win more contracts. ProovStation will present its latest portal at Eureka Park booth 50841.
ABOUT BCA
BCA works with OEMs, fleet operators and dealers to provide the backbone of Europe's automotive supply chain, remarketing 1.4 million vehicles annually.
From technical and logistics services for new vehicles, refurbishment, storage and logistics for the growing used sector and the core remarketing and auction operation, BCA offers the economies of scale and diversity of services to meet the needs of an impressive portfolio of customers.
As the automotive industry faces a period of unprecedented change, BCA is uniquely placed to deliver a range of linked services through the combined infrastructure of de-fleet facilities, vehicle logistics and preparation centres and physical, hybrid and digital remarketing channels.
BCA is investing and innovating today to deliver accurate real-time decision intelligence capability that allow its customers to operate seamlessly in both physical and digital markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200109005586/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom